Sandra Cobo

Sandra Cobo

Auto-generated profile, based on publicly available information

Sandra Cobo

Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Clinic Barcelona Comprehensive Cancer Center, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
ESEsther Sanfeliu
Esther Sanfeliu
AMAnabel Martínez-Romero
Anabel Martínez-Romero
MMMercedes Marín-Aguilera
Mercedes Marín-Aguilera
SCSandra Cobo
Sandra Cobo
BGBlanca González-Farré
Blanca González-Farré
APAleix Prat
Aleix Prat
Purpose: HER2DX is a validated genomic assay used to support treatment decisions in early-stage HER2-positive (HER2+) breast cancer. It provides three scores: relapse risk, likelihood of pathologic complete response (pCR), and ERBB2 mRNA expression. This study aimed to evaluate the association between HER2DX and histopathologic features and assess its relationship with pCR after neoadjuvant therapy. Experimental Design: Patients with newly diagnosed stage I to III HER2+ breast cancer were analyzed based on available HER2DX results during routine care in Spain (January 2022–June 2025). Centralized HER2DX testing was performed on formalin-fixed, paraffin-embedded tumor samples. Histopathologic analysis included tumor grade, hormone receptor status, histologic subtype, Ki67 index, HER2 IHC score, stromal tumor-infiltrating lymphocytes (TIL), tertiary lymphoid structures, and spatial immune distribution. Univariate and multivariable logistic regression analyses were conducted to identify factors associated with pCR after neoadjuvant trastuzumab-based therapy. Results: A total of 410 HER2+ tumors were analyzed, and 250 patients received neoadjuvant trastuzumab-based therapy with available surgical outcomes (36% achieved a pCR). HER2DX pCR scores were significantly associated with all eight histopathologic features, whereas relapse risk and ERBB2 scores were associated with five and two, respectively. TIL correlated with the immune/immunoglobulin signature (r = 0.59), and Ki67 with the proliferation signature (r = 0.50). The HER2DX pCR score remained the only independent predictor of pCR in multivariable analysis (OR, 1.77; 95% confidence interval, 1.08–2.97; P = 0.030). Conclusions: HER2DX reflects key biological and pathologic features of HER2+ breast cancer and independently predicts pCR, supporting its utility for individualized treatment decision-making.

2 July 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
SSShane Stecklein
Shane Stecklein
MMMiguel Martin
Miguel Martin
GVGuillermo Villacampa
Guillermo Villacampa
MMMaría del Monte-Millan
María del Monte-Millan
RYRachel Yoder
Rachel Yoder
PSPriyanka Sharma
Priyanka Sharma
Patients with triple-negative breast cancer (TNBC) who achieve pathologic complete response (pCR) to neoadjuvant systemic therapy have favorable survival, while those with residual disease have high recurrence risk. Stromal tumor infiltrating lymphocytes (sTILs) and TNBC-DX both predict pCR in TNBC. Whether these 2 biomarkers provide complementary information has not been tested. We evaluated sTILs and TNBC-DX in TNBC patients treated with docetaxel-carboplatin (TCb) on the MMJ-CAR-2014-01 study (NCT01560663) or TCb plus pembrolizumab (TCb+Pem) on the NeoPACT trial (NCT03639948). sTILs and TNBC-DX independently predicted pCR in patients treated with TCb+Pem. Patients with sTILs ≥ 30% and a TNBC-DX pCR-high genomic score achieved a pCR rate of 91.3% with TCb+Pem. An integrated classification incorporating sTILs and TNBC-DX identified approximately 40% of the NeoPACT cohort with a pCR rate exceeding 85%. The integrated classification was prognostic for event-free survival in patients treated with TCb+Pem. Integrating sTILs and TNBC-DX may facilitate chemoimmunotherapy escalation and de-escalation trials.

4 February 2026
Verified
Other
Open access
ESEsther Sanfeliu
Esther Sanfeliu
AMAnabel Martínez-Romero
Anabel Martínez-Romero
MMMercedes Marín-Aguilera
Mercedes Marín-Aguilera
SCSandra Cobo
Sandra Cobo
BGBlanca González-Farré
Blanca González-Farré
APAleix Prat
Aleix Prat
Associations between HER2DX scores and histopathologic variables.

4 February 2026
Verified
Other
Open access
ESEsther Sanfeliu
Esther Sanfeliu
AMAnabel Martínez-Romero
Anabel Martínez-Romero
MMMercedes Marín-Aguilera
Mercedes Marín-Aguilera
SCSandra Cobo
Sandra Cobo
BGBlanca González-Farré
Blanca González-Farré
APAleix Prat
Aleix Prat
Associations between HER2DX pCR score and standard pathologic features. Distribution of HER2DX pCR score groups (low, medium, and high; A); HER2DX pCR score by tumor grade (B), HR status (C), HER2 IHC status (D), TLS status (E), and spatial immune distribution (F). All scores are shown on a continuous scale from 1 to 99. Boxplots show IQR with medians indicated and display score distributions across groups. Statistical comparisons were performed using appropriate parametric tests.

4 February 2026
Verified
Other
Open access
ESEsther Sanfeliu
Esther Sanfeliu
AMAnabel Martínez-Romero
Anabel Martínez-Romero
MMMercedes Marín-Aguilera
Mercedes Marín-Aguilera
SCSandra Cobo
Sandra Cobo
BGBlanca González-Farré
Blanca González-Farré
APAleix Prat
Aleix Prat
Purpose:HER2DX is a validated genomic assay used to support treatment decisions in early-stage HER2-positive (HER2+) breast cancer. It provides three scores: relapse risk, likelihood of pathologic complete response (pCR), and ERBB2 mRNA expression. This study aimed to evaluate the association between HER2DX and histopathologic features and assess its relationship with pCR after neoadjuvant therapy.Experimental Design:Patients with newly diagnosed stage I to III HER2+ breast cancer were analyzed based on available HER2DX results during routine care in Spain (January 2022–June 2025). Centralized HER2DX testing was performed on formalin-fixed, paraffin-embedded tumor samples. Histopathologic analysis included tumor grade, hormone receptor status, histologic subtype, Ki67 index, HER2 IHC score, stromal tumor-infiltrating lymphocytes (TIL), tertiary lymphoid structures, and spatial immune distribution. Univariate and multivariable logistic regression analyses were conducted to identify factors associated with pCR after neoadjuvant trastuzumab-based therapy.Results:A total of 410 HER2+ tumors were analyzed, and 250 patients received neoadjuvant trastuzumab-based therapy with available surgical outcomes (36% achieved a pCR). HER2DX pCR scores were significantly associated with all eight histopathologic features, whereas relapse risk and ERBB2 scores were associated with five and two, respectively. TIL correlated with the immune/immunoglobulin signature (r = 0.59), and Ki67 with the proliferation signature (r = 0.50). The HER2DX pCR score remained the only independent predictor of pCR in multivariable analysis (OR, 1.77; 95% confidence interval, 1.08–2.97; P = 0.030).Conclusions:HER2DX reflects key biological and pathologic features of HER2+ breast cancer and independently predicts pCR, supporting its utility for individualized treatment decision-making.

4 February 2026
Verified
Other
Open access
ESEsther Sanfeliu
Esther Sanfeliu
AMAnabel Martínez-Romero
Anabel Martínez-Romero
MMMercedes Marín-Aguilera
Mercedes Marín-Aguilera
SCSandra Cobo
Sandra Cobo
BGBlanca González-Farré
Blanca González-Farré
APAleix Prat
Aleix Prat
Associations between HER2DX ERBB2 score and pathologic variables. Distribution of HER2DX ERBB2 score groups (low, medium, and high; A); HER2DX ERBB2 score by tumor grade (B), HR status (C), HER2 IHC status (D), TLS status (E), and spatial immune distribution (F). All scores are shown on a continuous scale from 1 to 99. Boxplots show IQR with medians indicated and display score distributions across groups. Statistical comparisons were performed using appropriate parametric tests.